These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39218648)

  • 21. Isavuconazonium sulfate: a new agent for the treatment of invasive aspergillosis and invasive mucormycosis.
    Kovanda LL; Maher R; Hope WW
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):887-97. PubMed ID: 27160418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.
    Wilby KJ
    Eur J Drug Metab Pharmacokinet; 2018 Jun; 43(3):281-290. PubMed ID: 29101732
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study).
    Kovanda LL; Desai AV; Lu Q; Townsend RW; Akhtar S; Bonate P; Hope WW
    Antimicrob Agents Chemother; 2016 Aug; 60(8):4568-76. PubMed ID: 27185799
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.
    Murrell D; Bossaer JB; Carico R; Harirforoosh S; Cluck D
    Int J Pharm Pract; 2017 Feb; 25(1):18-30. PubMed ID: 27569742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High isavuconazole plasma levels in a patient with possible invasive pulmonary aspergillosis and cirrhosis.
    Arsiè E; Piconi S; Iavarone M; Cozzi V; Lampertico P; Cattaneo D
    Eur J Clin Pharmacol; 2018 Aug; 74(8):1089-1090. PubMed ID: 29666903
    [No Abstract]   [Full Text] [Related]  

  • 26. Graded isavuconazole introduction in a patient with voriconazole allergy.
    Morales MK; Harris C; Shoham S
    Transpl Infect Dis; 2017 Dec; 19(6):. PubMed ID: 28851131
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological management of antifungal agents in pulmonary aspergillosis: an updated review.
    Echeverria-Esnal D; Martín-Ontiyuelo C; Navarrete-Rouco ME; Barcelo-Vidal J; Conde-Estévez D; Carballo N; De-Antonio Cuscó M; Ferrández O; Horcajada JP; Grau S
    Expert Rev Anti Infect Ther; 2022 Feb; 20(2):179-197. PubMed ID: 34328373
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic Pulmonary Aspergillosis: Clinical Presentation and Management.
    Evans TJ; Lawal A; Kosmidis C; Denning DW
    Semin Respir Crit Care Med; 2024 Feb; 45(1):88-101. PubMed ID: 38154471
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.
    Desai AV; Kovanda LL; Hope WW; Andes D; Mouton JW; Kowalski DL; Townsend RW; Mujais S; Bonate PL
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923872
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of Mucositis on Absorption and Systemic Drug Exposure of Isavuconazole.
    Kovanda LL; Marty FM; Maertens J; Desai AV; Lademacher C; Engelhardt M; Lu Q; Hope WW
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28289034
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Successful Treatment of Chronic Pulmonary Aspergillosis With Isavuconazole.
    Guillen Vera D; Ruiz Ruigómez M; García Moguel I; Morales Ruiz R; Corbella L; Fernández Rodríguez C
    J Investig Allergol Clin Immunol; 2019; 29(6):459-460. PubMed ID: 31172952
    [No Abstract]   [Full Text] [Related]  

  • 32. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: Challenges and lessons of the VITAL trial.
    Perfect JR; Cornely OA; Heep M; Ostrosky-Zeichner L; Mullane KM; Maher R; Croos-Dabrera R; Lademacher C; Engelhardt M; Chen C; Marty FM
    Mycoses; 2018 Jul; 61(7):420-429. PubMed ID: 29570857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Real-world challenges and unmet needs in the diagnosis and treatment of suspected invasive pulmonary aspergillosis in patients with haematological diseases: An illustrative case study.
    Hoenigl M; Prattes J; Neumeister P; Wölfler A; Krause R
    Mycoses; 2018 Mar; 61(3):201-205. PubMed ID: 29112326
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Isavuconazole Treatment of Cerebral and Pulmonary Aspergillosis in a Pediatric Patient With Acute Lymphoblastic Leukemia: Case Report and Review of Literature.
    De Leonardis F; Novielli C; Giannico B; Mariggiò MA; Castagnola E; Santoro N
    J Pediatr Hematol Oncol; 2020 Aug; 42(6):e469-e471. PubMed ID: 31094909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic drug concentrations of isavuconazole following the administration of isavuconazonium sulfate capsules via gastro-jejunum tube: A case report.
    Adamsick ML; Elshaboury RH; Gift T; Mansour MK; Kotton CN; Gandhi RG
    Transpl Infect Dis; 2019 Apr; 21(2):e13048. PubMed ID: 30636363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-frequency triazole resistance found In nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease.
    Denning DW; Park S; Lass-Florl C; Fraczek MG; Kirwan M; Gore R; Smith J; Bueid A; Moore CB; Bowyer P; Perlin DS
    Clin Infect Dis; 2011 May; 52(9):1123-9. PubMed ID: 21467016
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct in vitro comparison of the prodrug isavuconazonium sulfate with the isavuconazole active compound against Aspergillus spp. and 2 rare moulds.
    Pfaller MA; Rhomberg PR; Castanheira M
    Diagn Microbiol Infect Dis; 2018 Sep; 92(1):43-45. PubMed ID: 29735424
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Management of chronic pulmonary aspergillosis.
    Izumikawa K; Tashiro M; Kohno S
    Ann N Y Acad Sci; 2012 Dec; 1272():40-8. PubMed ID: 23231713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.
    Chitasombat MN; Kontoyiannis DP
    Expert Opin Pharmacother; 2015; 16(10):1543-58. PubMed ID: 26100603
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases.
    Kaindl T; Andes D; Engelhardt M; Saulay M; Larger P; Groll AH
    J Antimicrob Chemother; 2019 Mar; 74(3):761-767. PubMed ID: 30476108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.